Efficient electroporation of neuronal cells using synthetic oligonucleotides

Identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression

Xiulong Shen, Sharon Beasley, Jennifer N. Putman, Yanjie Li, Thahza P. Prakash, Frank Rigo, Marek Napierala, David R Corey

Research output: Contribution to journalArticle

Abstract

Oligonucleotide drugs are experiencing greater success in the clinic, encouraging the initiation of new projects. Resources are insufficient to develop every potentially important project, and persuasive experimental data using cell lines close to disease target tissue is needed to prioritize candidates. Friedreich’s ataxia (FRDA) is a devastating and currently incurable disease caused by insufficient expression of the enzyme frataxin (FXN). We have previously shown that synthetic nucleic acids can activate FXN expression in human patient-derived fibroblast cells. We chose to further test these compounds in induced pluripotent stem cell-derived neuronal progenitor cells (iPSC-NPCs). Here we describe methods to deliver oligonucleotides and duplex RNAs into iPSC-NPCs using electroporation. Activation of FXN expression is potent, easily reproducible, and potencies parallel those determined using patient-derived fibroblast cells. A duplex RNA and several antisense oligonucleotides (ASOs) with different combinations of 2′′-methoxyethyl (2′′-MOE), 2′′-fluoro (2′′-F), and constrained ethyl (cEt) were active, providing multiple starting points for further development and highlighting improved potency as an important goal for preclinical development. Our data support the conclusion that ASO-mediated activation of FXN is a feasible approach for treating FRDA and that electroporation is a robust method for introducing ASOs to modulate gene expressions in neuronal cells.

Original languageEnglish (US)
Pages (from-to)1118-1129
Number of pages12
JournalRNA
Volume25
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Artificial Cells
Electroporation
Antisense Oligonucleotides
Oligonucleotides
RNA
Friedreich Ataxia
Induced Pluripotent Stem Cells
Stem Cells
Fibroblasts
Nucleic Acids
Gene Expression
Cell Line
frataxin
Enzymes
Pharmaceutical Preparations

Keywords

  • Antisense oligonucleotide
  • Electroporation
  • Frataxin
  • Gene activation
  • Therapeutic development

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Efficient electroporation of neuronal cells using synthetic oligonucleotides : Identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression. / Shen, Xiulong; Beasley, Sharon; Putman, Jennifer N.; Li, Yanjie; Prakash, Thahza P.; Rigo, Frank; Napierala, Marek; Corey, David R.

In: RNA, Vol. 25, No. 9, 01.01.2019, p. 1118-1129.

Research output: Contribution to journalArticle

Shen, Xiulong ; Beasley, Sharon ; Putman, Jennifer N. ; Li, Yanjie ; Prakash, Thahza P. ; Rigo, Frank ; Napierala, Marek ; Corey, David R. / Efficient electroporation of neuronal cells using synthetic oligonucleotides : Identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression. In: RNA. 2019 ; Vol. 25, No. 9. pp. 1118-1129.
@article{981fdd8dadc749c9b8f0e11487218f8a,
title = "Efficient electroporation of neuronal cells using synthetic oligonucleotides: Identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression",
abstract = "Oligonucleotide drugs are experiencing greater success in the clinic, encouraging the initiation of new projects. Resources are insufficient to develop every potentially important project, and persuasive experimental data using cell lines close to disease target tissue is needed to prioritize candidates. Friedreich’s ataxia (FRDA) is a devastating and currently incurable disease caused by insufficient expression of the enzyme frataxin (FXN). We have previously shown that synthetic nucleic acids can activate FXN expression in human patient-derived fibroblast cells. We chose to further test these compounds in induced pluripotent stem cell-derived neuronal progenitor cells (iPSC-NPCs). Here we describe methods to deliver oligonucleotides and duplex RNAs into iPSC-NPCs using electroporation. Activation of FXN expression is potent, easily reproducible, and potencies parallel those determined using patient-derived fibroblast cells. A duplex RNA and several antisense oligonucleotides (ASOs) with different combinations of 2′′-methoxyethyl (2′′-MOE), 2′′-fluoro (2′′-F), and constrained ethyl (cEt) were active, providing multiple starting points for further development and highlighting improved potency as an important goal for preclinical development. Our data support the conclusion that ASO-mediated activation of FXN is a feasible approach for treating FRDA and that electroporation is a robust method for introducing ASOs to modulate gene expressions in neuronal cells.",
keywords = "Antisense oligonucleotide, Electroporation, Frataxin, Gene activation, Therapeutic development",
author = "Xiulong Shen and Sharon Beasley and Putman, {Jennifer N.} and Yanjie Li and Prakash, {Thahza P.} and Frank Rigo and Marek Napierala and Corey, {David R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1261/rna.071290.119",
language = "English (US)",
volume = "25",
pages = "1118--1129",
journal = "RNA",
issn = "1355-8382",
publisher = "Cold Spring Harbor Laboratory Press",
number = "9",

}

TY - JOUR

T1 - Efficient electroporation of neuronal cells using synthetic oligonucleotides

T2 - Identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression

AU - Shen, Xiulong

AU - Beasley, Sharon

AU - Putman, Jennifer N.

AU - Li, Yanjie

AU - Prakash, Thahza P.

AU - Rigo, Frank

AU - Napierala, Marek

AU - Corey, David R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Oligonucleotide drugs are experiencing greater success in the clinic, encouraging the initiation of new projects. Resources are insufficient to develop every potentially important project, and persuasive experimental data using cell lines close to disease target tissue is needed to prioritize candidates. Friedreich’s ataxia (FRDA) is a devastating and currently incurable disease caused by insufficient expression of the enzyme frataxin (FXN). We have previously shown that synthetic nucleic acids can activate FXN expression in human patient-derived fibroblast cells. We chose to further test these compounds in induced pluripotent stem cell-derived neuronal progenitor cells (iPSC-NPCs). Here we describe methods to deliver oligonucleotides and duplex RNAs into iPSC-NPCs using electroporation. Activation of FXN expression is potent, easily reproducible, and potencies parallel those determined using patient-derived fibroblast cells. A duplex RNA and several antisense oligonucleotides (ASOs) with different combinations of 2′′-methoxyethyl (2′′-MOE), 2′′-fluoro (2′′-F), and constrained ethyl (cEt) were active, providing multiple starting points for further development and highlighting improved potency as an important goal for preclinical development. Our data support the conclusion that ASO-mediated activation of FXN is a feasible approach for treating FRDA and that electroporation is a robust method for introducing ASOs to modulate gene expressions in neuronal cells.

AB - Oligonucleotide drugs are experiencing greater success in the clinic, encouraging the initiation of new projects. Resources are insufficient to develop every potentially important project, and persuasive experimental data using cell lines close to disease target tissue is needed to prioritize candidates. Friedreich’s ataxia (FRDA) is a devastating and currently incurable disease caused by insufficient expression of the enzyme frataxin (FXN). We have previously shown that synthetic nucleic acids can activate FXN expression in human patient-derived fibroblast cells. We chose to further test these compounds in induced pluripotent stem cell-derived neuronal progenitor cells (iPSC-NPCs). Here we describe methods to deliver oligonucleotides and duplex RNAs into iPSC-NPCs using electroporation. Activation of FXN expression is potent, easily reproducible, and potencies parallel those determined using patient-derived fibroblast cells. A duplex RNA and several antisense oligonucleotides (ASOs) with different combinations of 2′′-methoxyethyl (2′′-MOE), 2′′-fluoro (2′′-F), and constrained ethyl (cEt) were active, providing multiple starting points for further development and highlighting improved potency as an important goal for preclinical development. Our data support the conclusion that ASO-mediated activation of FXN is a feasible approach for treating FRDA and that electroporation is a robust method for introducing ASOs to modulate gene expressions in neuronal cells.

KW - Antisense oligonucleotide

KW - Electroporation

KW - Frataxin

KW - Gene activation

KW - Therapeutic development

UR - http://www.scopus.com/inward/record.url?scp=85071706334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071706334&partnerID=8YFLogxK

U2 - 10.1261/rna.071290.119

DO - 10.1261/rna.071290.119

M3 - Article

VL - 25

SP - 1118

EP - 1129

JO - RNA

JF - RNA

SN - 1355-8382

IS - 9

ER -